Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2020Leukemia & lymphoma/Leukemia and lymphoma

Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMary Ann AndersonThe Royal Melbourne HospitalJohn F. SeymourJohn F. SeymourSouth Australia Pathology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Anderson et al. (2020) studied this question.

synapsesocial.com/papers/6a734ebb4e82b1a46ac67934https://doi.org/10.1080/10428194.2020.1802454
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus2010 · 570 citations
  2. 2Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies2016 · 147 citations
  3. 3Bendamustine associated immune suppression and infections during therapy of hematological malignancies2015 · 78 citations
  4. 4Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2018 · 939 citations
  5. 5Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States2018 · 166 citations